An end to the Aids epidemic could be in sight after a landmark study found men whose HIV infection was fully suppressed by antiretroviral drugs had no chance of infecting their partner.
The success of the medicine means that if everyone with HIV were fully treated, there would be no further infections.
Among nearly 1,000 male couples across Europe where one partner with HIV was receiving treatment to suppress the virus, there were no cases of transmission of the infection to the HIV-negative partner during sex without a condom. Although 15 men were infected with HIV during the eight-year study, DNA testing proved that was through sex with someone other than their partner who was not on treatment.
Gilead Announces New Data on the Impact of Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
FOSTER CITY, Calif.–(BUSINESS WIRE)–Jul. 24, 2018– Gilead Sciences, Inc.(NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada(emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP) use across all 50 U.S. states and theDistrict of Columbia. Conducted in collaboration with researchers at Emory University Rollins School of Public Health and the Centers for Disease Control and Prevention(CDC), these data demonstrate that use of once-daily oral Truvada for PrEP has had an independent and significant impact on the number of new HIV infections diagnosed in the United States from 2012 to 2016. The data were presented at the 22ndInternational AIDS Conference (AIDS 2018) in Amsterdam.
Truvada for PrEP is indicated in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg. To take Truvada for PrEP, individuals must be confirmed to be HIV-negative and be tested for HIV immediately prior to initiating and at least every 3 months while taking Truvada for PrEP. Truvada has a boxed warning in its product label regarding the risks of drug resistance with the use of Truvada for PrEP in undiagnosed early HIV infection and post treatment acute exacerbation of hepatitis B. Further important safety information, adverse drug reactions, and prescribing considerations are included below…..
Results from a retrospective nationwide analysis on the impact of Truvada (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) showed that its use resulted in significant declines in new HIV infections in the US from 2012 to 2016. Findings from the study were presented at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam.
Using the National HIV Surveillance System and national pharmacy data, researchers from Emory University Rollins School of Public Health and the Centers for Disease Control and Prevention (CDC) found that across the US, the prevalence in the use of Truvada for PrEP increased from 7.0 to 68.5 per 1000 persons at highest risk for HIV during the 5-year period. In that same period, the rate of new HIV diagnoses among the general population decreased significantly from 15.7 to 14.5 per 100,000 persons…..